We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
RHOLISTIQ (Kadmon Oceania Pty Ltd)
Product name
RHOLISTIQ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
160 (255 working days)
Active ingredients
belumosudil mesilate
Registration type
NCE/NBE
Indication
RHOLISTIQ (film-coated tablet) is indicated for the treatment of patients with chronic graft-versus-host disease (chronic GVHD) aged 12 years and older who have an inadequate response to corticosteroids.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.